Biopharma Perspective on Early Venture Investing and R&D
Join us for a lively panel discussion with Marian Nakada (Johnson & Johnson Innovation – JJDC), Bob Silverman (Roche) and Steven Weinstein (Novartis Ventures), moderated by CTV’s executive director Orin Herskowitz. The conversation will touch on the various ways Big Pharma & Biotech are using venture capital investing, regional innovation centers, joint ventures, university research sponsorship, and IP licensing to source their next blockbuster products (as well as generate equity returns). The panelists will share their perspectives on venture capital investing strategies in biopharma, how to pitch strategic investors, the surge in biotech IPOs, hot research areas within biopharma, and best practices for establishing R&D partnerships between industry and academia.
This event is co-sponsored by Columbia Engineering, the Eugene Lang Center for Entrepreneurship, Columbia Entrepreneurship, and the Healthcare and Pharmaceutical Management Program at Columbia Business School.
Vice President, Venture Investments, Johnson & Johnson Innovation – JJDC
Marian Nakada, Ph.D, Vice President, Venture Investments, joined Johnson & Johnson Innovation - JJDC, Inc. (JJDC) in 2013. She is based in Boston, Mass. and focuses on pharmaceutical investments in East Coast companies that will create options in areas of strategic interest to Johnson & Johnson. Marian previously held roles in Centocor, Janssen R&D and Janssen Business Development. She has authored 62 peer-reviewed publications and 14 book chapters and reviews. She has a B.A. in Biology from Harvard College and a Ph.D in Pharmacology from the University of Pennsylvania and currently sits on the boards of Navitor Pharmaceuticals and Padlock Therapeutics.
Head of Externalized Drug Discovery Partnering, Roche
Bob has been with Roche for 23 years. In his current role as Head of Externalized Drug Discovery Partnering, he leads business development activities for externalized drug discovery, and maintains venture capital relationships on behalf of the Roche Pharma division. Previously Bob worked as a Venture Capital Lead at Roche for three years and as Global Licensing Director for seven years, where Bob led transaction activities and negotiations related to product and technology licensing and asset management. Prior to that role, Bob was a Global Licensing Attorney for the Pharma Licensing Group, as well as a Senior Counsel for the US Affiliate patent department. He earned his JD from Boston University School of Law and his bachelor's degree from Franklin & Marshall College.
Managing Partner, Novartis Venture Fund
Steven D. Weinstein is a Managing Director in Cambridge, Mass. Steve focuses on both medical device and therapeutic investments for the fund. Prior to joining NVF, he was a Principal at Prism Venture Partners where he focused on medical devices. Prior to Prism, Steve was a Principal and Kauffman Fellow with Mid-Atlantic Venture Funds. He started his career as turnaround CEO, raising angel funds to buy the assets of a defunct distribution business out of bankruptcy and subsequently rebuilding the business. Steve holds an MBA with distinction from the University of Michigan Business School and a B.S. in mechanical engineering from Columbia University’s School of Engineering and Applied Science. He serves on the Partner’s Healthcare Innovation Advisory Board and the University of Michigan Wolverine Venture Fund Advisory Board. Steve serves on the boards of Advanced Animal Diagnostics, Autonomic Technologies, Innocrin, Intersection Medical and Viamet.